mRNA vaccine shows promise for treating age-related macular degeneration
Peer-Reviewed Publication
Updates every hour. Last Updated: 29-Dec-2025 20:11 ET (30-Dec-2025 01:11 GMT/UTC)
An mRNA vaccine developed by researchers from Japan suppressed abnormal blood vessel growth or neovascularization in the retina of mouse models. Neovascularization is a condition that is caused by age-related macular degeneration (AMD), a leading cause of vision loss for elderly people. The vaccine can be delivered intramuscularly and is as effective as current therapies that require frequent eye injections, offering a more comfortable and easier-to-administer alternative for treating AMD and other neovascular eye diseases.
Researchers engineered mice with a mutation (E3896A) in the RyR1 calcium-binding site, eliminating calcium-induced calcium release (CICR) without affecting depolarization-induced calcium release. The mutation preserved normal skeletal muscle performance but protected against malignant hyperthermia and heat stroke in disease models. These findings demonstrate that CICR has little role in healthy excitation–contraction coupling but may contribute to pathology when hyperactivated.
Researchers from the Research Center for Materials Nanoarchitectonics (MANA), one of the centers under the National Institute for Materials Science (NIMS), Japan, report an inexpensive iron hydroxide catalyst that could support the use of sodium borohydride as a hydrogen storage material.
World's first successful development of innovative nanocomposites comprising lactic acid bacteria components and liquid metal
Selective tumor accumulation via EPR effect with demonstrated visualization and therapeutic efficacy in mouse-transplanted cancers
Complete cancer elimination through synergistic immune activation and photothermal conversion effects under near-infrared light irradiation
Confirmed excellent biocompatibility, promising new cancer diagnostic and therapeutic technologies